SecBot SecBot
6-K ·Filed Nov 2, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 6/10
Horizonmonths Processed14d 20h ago SEC0001648257-26-000074
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor EMA and MHLW review timelines and any advisory committee meetings. The US FDA NDA decision (PDUFA date) will be the next major catalyst. Also watch for potential pricing and reimbursement decisions in Europe and Japan.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$13.27
T+0 close · Nov 2, 2026 · via day close
Latest settled
+15.45%
T+5 · $15.32 · next T+20 in 14d
Vs SPY
+15.37%
α at T+5
Latest observation
+13.01%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $13.27entry
  2. T+1 · 14d ago −1.43%α −1.73% · $13.08
  3. T+5 · 8d ago +15.45%α +15.37% · $15.32
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated lung cancer have been accepted for review by the EMA in Europe and the MHLW in Japan, following a US FDA NDA submission in September 2026. The filings are supported by positive SAFFRON Phase III data showing statistically significant improvements in progression-free survival and overall survival versus chemotherapy. This expands the global regulatory pathway for the combination, which is already approved in China and temporarily authorized in Switzerland.

Key Facts

  • EMA validated and accepted MAA for ORPATHYS plus TAGRISSO in Europe for MET-overexpressed/amplified NSCLC after EGFR-TKI progression.
  • Japan MHLW accepted NDA for same combination in unresectable, advanced or recurrent NSCLC with MET overexpression/amplification after EGFR-TKI therapy.
  • US FDA NDA for the combination was submitted in September 2026.
  • SAFFRON Phase III trial showed PFS HR 0.55 (p<0.001), median PFS 7.6 vs 5.4 months; OS HR 0.68 (p=0.010), median OS 17.8 vs 12.9 months.
  • SAFFRON data presented at ESMO 2026 Presidential Symposium and published in The New England Journal of Medicine.
  • ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
  • Combination already approved in China (SACHI trial) and granted temporary authorization in Switzerland (SAVANNAH trial).

Financial Impact

Regulatory acceptance in Europe and Japan, following US submission, de-risks a potential multi-billion-dollar global peak sales opportunity for ORPATHYS in the MET-driven EGFR-mutated NSCLC setting. No specific revenue figures disclosed.

revenueroyalty income

Risk Factors

  • Regulatory outcomes are uncertain; the EMA or MHLW may request additional data or issue a complete response letter.
  • Competition from other MET-targeted therapies in development for the same indication.
  • Commercial uptake depends on reimbursement and physician adoption in each region.
  • ORPATHYS is partnered with AstraZeneca, so HUTCHMED's economics are a share of profits or royalties, not full revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000074
Document: hcm-20261102x6k.htm0001648257-26-000074
Document: 0001648257-26-000074-index-headers.html0001648257-26-000074
Document: 0001648257-26-000074-index.html0001648257-26-000074
Document: 0001648257-26-000074.txt0001648257-26-000074
Earnings Context (Synthetic; results releases only)0001648257-26-000074

Track record

33 reports on HCM

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
  2. Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
  3. Nov 2, 202614d ago 6-K Bullish 6/10 Viewing Entry $13.27 Now $14.73 +11.00% settles Jan 29
  4. Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
  5. Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
  6. Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  7. Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
  9. Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
  10. Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
Showing 10 of 33

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026